Table 1.
Author | Year | Country | Study design | Recruitment period | Age (median) | Case | Treatment setting | Measurement | Cutoff | High expression of VEGF | Survival analysis |
---|---|---|---|---|---|---|---|---|---|---|---|
Wang Q | 2013 | China | Retrospective | 1982-2007 | 34-85 (65.83) | 148 | Prostatectomy | IHC | Low VS high | 98 | CSS |
Vergis R | 2008 | UK | Prospective | 1995-2002 | 50-80 (67) | 201 | Radiotherapy | IHC | Low VS high | 34 | BF |
Vergis R | 2008 | UK | Prospective | 1995-2005 | 45-78 (61) | 278 | Prostatectomy | IHC | Low VS high | 14 | BF |
West AF | 2001 | UK | Prospective | 1989-1994 | 49-90 | 57 | Prostatectomy | IHC | Low VS high | 32 | CSS |
Shariat SF | 2004 | USA | Prospective | 1994-1995 | 40-80 (62.6) | 215 | Prostatectomy | ELISA | 9.9 pg/ml | _ | PFS |
Pan L | 2013 | Canada | Retrospective | -1991 | 55-81 (71) | 103 | Radiotherapy | IHC | 0-1 vs. 2-3 | 54 | OS DFS BF |
George DJ | 2001 | USA | Prospective | 1996-1998 | 62-75 (68) | 197 | Hormone therapy | ELISA | 260 pg/ml | 16 | OS |
Bok RA | 2001 | USA | Prospective | _ | 63-76 (70) | 100 | Hormone therapy | urine ELISA | 28 pg/ml | 50 | OS |
Green MM | 2007 | UK | Retrospective | 1995-2000 | _ | 50 | Radiotherapy | IHC | Low VS high | 28 | CSS |
Peyromaure M | 2007 | France | Prospective | 2005.06-11 | 57-68 (62) | 89 | Prostatectomy | IHC | Low VS high | 36 | PFS |
Fukuda H | 2007 | Japan | Retrospective | 1997-2003 | 5-83 (71) | 58 | Prostatectomy | IHC | Low VS high | _ | PFS |
Weber DC | 2012 | Switzerland | Prospective | 1994-2004 | 56-81 (69.1) | 103 | Radiotherapy | IHC | Low VS high | 76 | PFS |
Mori R | 2010 | USA | Retrospective | 1972-1999 | _ | 138 | Prostatectomy | PCR | 10.35 | 44 | OS DFS BF |
Abbreviations: CSS, cancer-specific survival; PFS, progression-free survival; OS, overall survival; DFS, disease-free survival; BF, biomedical failure; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; (-), not reported.